| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.08.078 |
| P698 | PubMed publication ID | 15020606 |
| P50 | author | Thomas Ind | Q42613157 |
| P2093 | author name string | Martin E Gore | |
| Roger A'Hern | |||
| Peter R Blake | |||
| Stanley B Kaye | |||
| Desmond P J Barton | |||
| Viviane Hess | |||
| K Harrington | |||
| D Michael King | |||
| John H Shepherd | |||
| J Bridges | |||
| Nazar Nasiri | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 1040-1044 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. | |
| P478 | volume | 22 |
| Q36614490 | A distinct molecular profile associated with mucinous epithelial ovarian cancer. |
| Q33365433 | Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. |
| Q30428479 | Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study |
| Q53859210 | Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. |
| Q33600629 | Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer |
| Q64889817 | An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. |
| Q51732590 | Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. |
| Q38617648 | Associations between residual disease and survival in epithelial ovarian cancer by histologic type |
| Q37480057 | Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. |
| Q37063391 | Bowel obstruction in elderly ovarian cancer patients: a population-based study |
| Q37345899 | CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study |
| Q33763357 | Calculator for ovarian carcinoma subtype prediction |
| Q36319518 | Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer |
| Q45933729 | Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. |
| Q55366217 | Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. |
| Q34742974 | Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome |
| Q37188831 | Classification of ovarian cancer: a genomic analysis. |
| Q37820754 | Classification of ovarian carcinomas based on pathology and molecular genetics |
| Q33618894 | Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer |
| Q37411776 | Clinicopathological characteristics of mucinous adenocarcinoma of the ovary |
| Q46483826 | Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. |
| Q36817504 | Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study |
| Q58096673 | Comparison of stage III mucinous and serous ovarian cancer: a case-control study |
| Q45836726 | Correlation of ALDH1 and Notch3 Expression: Clinical implication in Ovarian Carcinomas |
| Q64969004 | Current Status of Patient-Derived Ovarian Cancer Models. |
| Q36873800 | Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. |
| Q37219890 | Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. |
| Q57163930 | Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials |
| Q84574337 | Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial |
| Q50076405 | Early stage mucinous ovarian cancer: A review |
| Q80839222 | Editorial. Endometrioid epithelial ovarian cancer |
| Q91674970 | Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer |
| Q36150652 | Emerging drugs for ovarian cancer |
| Q31149715 | Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. |
| Q47140496 | Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. |
| Q36798420 | Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes |
| Q90482939 | Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer |
| Q92747182 | Evolving population-based statistics for rare epithelial ovarian cancers |
| Q38080036 | Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer |
| Q37875977 | Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary |
| Q39043741 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours |
| Q37937937 | First line therapy: have we made any improvement? |
| Q37179400 | Future directions in the management of epithelial ovarian cancer. |
| Q37094076 | Genetic and molecular changes in ovarian cancer |
| Q48877738 | Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). |
| Q34688984 | HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer |
| Q33517907 | HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy |
| Q40452749 | Histologic types of epithelial ovarian cancer: have they different risk factors? |
| Q56334183 | Histotype classification of ovarian carcinoma: A comparison of approaches |
| Q90396711 | Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma |
| Q54386228 | Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. |
| Q81297573 | Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) |
| Q38856683 | Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. |
| Q35783882 | Induction of ovarian cancer and DNA adducts by Dibenzo[a,l]pyrene in the mouse |
| Q88118089 | International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers |
| Q52714804 | Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. |
| Q36284514 | Investigational agents for epithelial ovarian cancer |
| Q98628597 | Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit |
| Q35954378 | Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries |
| Q37779240 | Making the best of PARP inhibitors in ovarian cancer |
| Q88791863 | Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses |
| Q40506716 | Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. |
| Q35872796 | Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy |
| Q38067436 | Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates |
| Q47254055 | Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. |
| Q84984261 | Molecular typing of epithelial ovarian carcinomas using inflammatory markers |
| Q36157106 | Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. |
| Q42917880 | Mucinous Adenocarcinoma of the Ovary |
| Q43751488 | Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy |
| Q37880475 | Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. |
| Q37249734 | Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients |
| Q38824322 | Mucinous epithelial ovarian carcinoma. |
| Q34667838 | Mucinous tumors of the ovary: current thoughts on diagnosis and management |
| Q33323250 | Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms |
| Q57285339 | PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer |
| Q36831864 | Palliative Surgical Approach in Advanced Nonresponsive Mucinous Ovarian Cancer: A Rare Case Report |
| Q44467711 | Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study |
| Q35776312 | Persistent low expression of hZip1 in mucinous carcinomas of the ovary, colon, stomach and lung |
| Q37139726 | Pharmaceutical management of ovarian cancer : current status |
| Q40419487 | Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia |
| Q35212386 | Prediction of resistance to chemotherapy in ovarian cancer: a systematic review |
| Q33983580 | Preliminary observations and clinical value of N-acetyl resonances in ovarian tumours using in-vivo proton MR spectroscopy at 3T. |
| Q34175056 | Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary |
| Q37777632 | Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer |
| Q30359038 | Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. |
| Q60302394 | Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study |
| Q35475560 | Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients |
| Q39872610 | Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs |
| Q35959074 | REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker |
| Q55056786 | RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. |
| Q36979335 | Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma |
| Q55609057 | Recent Insights into Mucinous Ovarian Carcinoma. |
| Q36622857 | Recent progress in the diagnosis and treatment of ovarian cancer |
| Q37094927 | Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma |
| Q36066178 | Role of chemotherapy in the management of epithelial ovarian cancer |
| Q83287534 | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial |
| Q88502356 | Rural-metropolitan disparities in ovarian cancer survival: a statewide population-based study |
| Q35429938 | Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary. |
| Q55163731 | Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer. |
| Q24307419 | Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer |
| Q35051543 | Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells |
| Q92967868 | Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base |
| Q81574407 | Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel |
| Q37486156 | Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology |
| Q37301884 | Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging |
| Q38165164 | Targeted therapies and clinical trials in ovarian cancer |
| Q37366157 | Targeting SRC and tubulin in mucinous ovarian carcinoma |
| Q33638051 | Targeting SRC in mucinous ovarian carcinoma. |
| Q60046966 | The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer |
| Q35663610 | The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors |
| Q82674487 | The heterogeneity of epithelial ovarian cancer: getting it right |
| Q93063911 | The molecular origin and taxonomy of mucinous ovarian carcinoma |
| Q80489408 | Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer |
| Q51817178 | Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. |
| Q33629082 | Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer |
| Q37613250 | Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. |
| Q28536689 | Type-specific cell line models for type-specific ovarian cancer research |
| Q84483062 | Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma |
| Q34695404 | Unmasking the complexities of mucinous ovarian carcinoma |
| Q36571743 | Update on first-line treatment of advanced ovarian carcinoma |
| Q38284239 | Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. |
| Q60938832 | When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy |
Search more.